HomeCompareNXSCF vs JEPQ

NXSCF vs JEPQ: Dividend Comparison 2026

NXSCF yields 10095.00% · JEPQ yields 11.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NXSCF wins by $60522276252191552.00M in total portfolio value
10 years
NXSCF
NXSCF
● Live price
10095.00%
Share price
$0.00
Annual div
$0.10
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$60522276252191552.00M
Annual income
$59,365,457,623,754,850,000,000.00
Full NXSCF calculator →
JEPQ
JPMorgan Nasdaq Equity Premium Income ETF
● Live price
11.10%
Share price
$55.52
Annual div
$6.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.8K
Annual income
$2,152.59
Full JEPQ calculator →

Portfolio growth — NXSCF vs JEPQ

📍 NXSCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNXSCFJEPQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NXSCF + JEPQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NXSCF pays
JEPQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NXSCF
Annual income on $10K today (after 15% tax)
$858,075.00/yr
After 10yr DRIP, annual income (after tax)
$50,460,638,980,191,620,000,000.00/yr
JEPQ
Annual income on $10K today (after 15% tax)
$943.83/yr
After 10yr DRIP, annual income (after tax)
$1,829.70/yr
At 15% tax rate, NXSCF beats the other by $50,460,638,980,191,620,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NXSCF + JEPQ for your $10,000?

NXSCF: 50%JEPQ: 50%
100% JEPQ50/50100% NXSCF
Portfolio after 10yr
$30261138126095776.00M
Annual income
$29,682,728,811,877,424,000,000.00/yr
Blended yield
98.09%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NXSCF buys
0
JEPQ buys
0
No recent congressional trades found for NXSCF or JEPQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNXSCFJEPQ
Forward yield10095.00%11.10%
Annual dividend / share$0.10$6.16
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$60522276252191552.00M$44.8K
Annual income after 10y$59,365,457,623,754,850,000,000.00$2,152.59
Total dividends collected$60445311406050536.00M$16.3K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: NXSCF vs JEPQ ($10,000, DRIP)

YearNXSCF PortfolioNXSCF Income/yrJEPQ PortfolioJEPQ Income/yrGap
1← crossover$1,020,200$1,009,500.00$11,930$1,110.39+$1.01MNXSCF
2$97,343,193$96,251,579.44$14,133$1,224.34+$97.33MNXSCF
3$8,687,260,875$8,583,103,657.69$16,632$1,340.46+$8687.24MNXSCF
4$725,171,452,913$715,876,083,776.83$19,454$1,457.97+$725171.43MNXSCF
5$56,624,484,726,557$55,848,551,271,940.71$22,626$1,576.08+$56624484.70MNXSCF
6$4,136,189,552,978,259$4,075,601,354,320,842.00$26,175$1,694.09+$4136189552.95MNXSCF
7$282,655,809,165,117,900$278,230,086,343,431,170.00$30,133$1,811.32+$282655809165.09MNXSCF
8$18,072,047,576,372,183,000$17,769,605,860,565,506,000.00$34,531$1,927.17+$18072047576372.15MNXSCF
9$1,081,138,905,081,034,700,000$1,061,801,814,174,316,400,000.00$39,403$2,041.08+$1081138905081034.75MNXSCF
10$60,522,276,252,191,556,000,000$59,365,457,623,754,850,000,000.00$44,787$2,152.59+$60522276252191552.00MNXSCF

NXSCF vs JEPQ: Complete Analysis 2026

NXSCFStock

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.

Full NXSCF Calculator →

JEPQETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →
📬

Get this NXSCF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NXSCF vs SCHDNXSCF vs JEPINXSCF vs ONXSCF vs KONXSCF vs MAINNXSCF vs XYLDNXSCF vs QYLDNXSCF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.